Rigel Pharmaceuticals, Inc. (RIGL)
Wall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High?
The consensus price target hints at a 72% upside potential for Rigel (RIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock Now
Rigel (RIGL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Is Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Earnings Estimates Rising for Rigel (RIGL): Will It Gain?
Rigel (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a Bet
The mean of analysts' price targets for Rigel (RIGL) points to an 82.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum
Rigel Pharmaceuticals, Inc. shows strong momentum, with a 68% YoY revenue increase, driven by TAVALISSE, GAVRETO, and REZLIDHIA, suggesting a shift to a durable growth stock. Q1 net income of $11.4M and improved gross margins highlight Rigel's operating leverage, reducing the need for dilutive fundraising and supporting future R&D investments. R289's promising pipeline progress and TAVALISSE's patent extension to 2032 bolster Rigel's long-term outlook, despite reliance on key products and competitive markets.
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary. Raul Rodriguez - President & Chief Executive Officer Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - Chief Financial Officer Conference Call Participants Kalpit Patel - B.
Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to loss of $0.50 per share a year ago.
Rigel (RIGL) Upgraded to Buy: What Does It Mean for the Stock?
Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability
Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability
Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to Trade
The mean of analysts' price targets for Rigel (RIGL) points to a 44.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary. Raul Rodriguez - President & Chief Executive Officer Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citi Kalpit Patel - B.
